Physician Detail
S. Diane Yamada

S. Diane Yamada, M.D.

Gynecologic Oncologist, NCH
Associate Professor & Section Chief, University of Chicago

Gynecologic Oncology

Request an appointment Print physician info

Board Certification(s)

Gynecologic Oncology


Academic Appointment

Faculty Appointment - University of Chicago


Group



Other Organization(s)

NCH Medical Group


Medical School

University of California (Los Angeles, California) 1987-1991


Internship

Harbor-UCLA Medical Center (Torrance, California)


Residency

Harbor-UCLA Medical Center (Torrance, California)


Fellowship

Cedars-Sinai Medical Center (Los Angeles, CA); University of California, Irvine (Orange, CA)


Primary Specialty

Gynecologic Oncology


Additional Specialties

Oncology Surgery


Clinical Interests

Achievements

Honors:

1995: American Association of Gynecologic Laparoscopists, Resident Award - ""Special Excellence in Endoscopy""
1995: American Association for Cancer Research, award to attend Molecular Biology in Clinical Oncology Workshop
2003: Recipient, “Golden Apple” Award, Department of Obstetrics and Gynecology, University of Chicago, for Outstanding Resident Teaching, 2002-2003
2003: Induction into AΩA (Alpha Omega Alpha Honor Medical Society) upon vote of the University of Chicago, Pritzker School of Medicine students, 2003-2004
2013: Best Doctors in America
2014: Chicago’s Top Doctors
2017: Chicago's Top Cancer Doctors

Publications:

  1. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY. Altered expression of transforming growth factor ligands and receptors in primary and recurrent ovarian carcinomas. Cancer 85(3):658-668, 1999. PMID 10091739
  2. Brewster WR, DiSaia PJ, Monk BJ, Ziogas A, Yamada SD, Anton-Culver H. Young age as prognostic factor in cervical cancer: results of a population based study. Am J Obstet Gynecol. 180(6) 1464-67, 1999. PMID 10368490
  3. Le T, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 73(3): 461-63, 1999. PMID 10366480
  4. Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGF-ß1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 75: 72-77, 1999. PMID 10502429
  5. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88 (12): 2782-6, 2000. PMID 10870061
  6. Rotmensch J, Connell PP, Yamada SD, Waggoner SE, Mundt AJ. One versus two intracavitary brachytherapy applications in early-stage cervical cancer patients undergoing definitive radiation therapy. Gynecol Oncol 78, 32-38, 2000. PMID 10873406
  7. Mundt AJ, Waggoner S, Yamada SD, Rotmensch J, Connell PP. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol 79 (1): 79-85, 2000. PMID 11006036
    Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada SD, Mundt, AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiation Oncology Bio Phys 48:1613-1621, 2000. PMID 11121668
  8. Brewster WR, Monk BJ, Ziogas A, Anton-Culver H, Yamada SD, Berman ML. An intent to treat analysis of stage IB and IIa Cervical Cancer in the United States: Radiotherapy or surgery 1988-1995. Obstet Gynecol 97:248-54, 2001. PMID 11165590
  9. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50:1145-53, 2001. PMID 11483323
  10. Mundt AJ, Murphy KT, Rotmensch R, Waggoner SE, Yamada SD, Connell PP. Surgery and postoperative radiation therapy in FIGO stage IIIC endometrial carcinoma. Int J Radiat Oncol Bio Phys 50:1154-60, 2001. PMID 11483324
  11. Mundt AJ, Roeske JC, Lujan A, Yamada SD, Waggoner SE, Fleming GF, Rotmensch J. Initial clinical experience with intensity modulated whole pelvic radiation therapy in women with gynecologic malignancies. Gynecol Oncol 82:456-63, 2001. PMID 11520140
  12. Ashman JB, Connell PP, Yamada SD, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 82:338-343, 2001. PMID 11531290
  13. Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Langhauser SC, Fleming GF. Phase 1 trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 82:333-7, 2001. PMID 11531289
  14. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncology Biol Phys 50:1145-53, 2001. PMID 11483323
  15. Adams SF, Yamada SD, Montag A, Rotmensch J. An a-fetoprotein-producing hepatoid adenocarcinoma of the endometrium. Gynecol Oncol 83:418-421, 2001. PMID 11606109
    Phelan C, Montag AG, Rotmensch J, Waggoner SE, Yamada SD, Mundt AJ. Outcome and management of pathological stage 1 endometrial carcinoma patients with involvement of lower uterine segment. Gynecol Oncol 83:513-17, 2001. PMID 11733964
  16. Mundt AJ, Lujan A, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat Oncology Bio Phys 52:1330-37, 2002. PMID 11955746 
  17. Yamada SD, Hickson J, Hrobowski Y, Vander Griend DJ, Hickson JA, Benson D, Montag A, Karrison T, Huo D, Rutgers J, Adams S, Rinker-Schaeffer C. Mitogen- activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Research, 62:6717-6723, 2002. PMID 12438272 
  18. Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54:1388-96, 2002. PMID 12459361
  19. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 55:1272-6, 2003. PMID 12654437
  20. Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 57:516-21, 2003. PMID 12957265
  21. Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada D, Montag AG, Mundt AJ. Prognostic significance of decreased E-cadherin protein expression in pathologic stage I-III endometrial cancer: an immunohistochemical analysis. Int J Radiat Oncol Biol Phy 57:S402-3, 2003. ISSN: 0360-3016
  22. Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 13:749-55, 2003. PMID 14675310
    Rana S, Warren B, Yamada SD. Stage IIIC small cell carcinoma of the ovary: Survival with conservative surgery and chemotherapy. Obstet Gynecol 103:1120-3, 2004. PMID 15121630
  23. Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GF. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 92:801-5, 2004. PMID 14984944
  24. Citron JR, Sutton H, Yamada SD, Mehta N, Mundt AJ. Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys, 59:1432-8, 2004. PMID 15275729
  25. Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJ. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 10:5546-53, 2004. PMID 15328195
  26. Schroder MA, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Waggoner SE, Yamada SD, Small, Jr. W, Mundt AJ. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys 61:1078-86, 2005. PMID 15752887
  27. Dewdney S, Sokoloff M, Yamada SD. Conservative management of chylous ascites after removal of a symptomatic growing retroperitoneal teratoma. Gynecol Oncol 100:608-611, 2006. PMID 16226796
  28. Hickson JA, Huo D, Vander Griend DJ, Rinker-Schaeffer CW, Tomek R, Karrison T, Yamada SD. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 66:2264-2270, 2006. PMID 16489030
  29. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Lengyel E, Yamada SD, Collins Y, Hurteau J, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66:1356-65, 2006. PMID 16757127
  30. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 15; 67(4):1670-9, 2007. PMID 17308108
  31. Adams SF, Hickson JA, Hutto J, Montag AM, Lengyel E, Tomek R, Yamada SD. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecologic Oncology 104 (3):524-8, 2007. PMID 17049587
  32. McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 105(2):508-16, 2007. PMID 17306350
  33. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 121(7):1463-72, 2007. PMID 17546601
  34. Lotan TL, Tefs K, Schuster V, Miller JL, Manaligod JR, Filstead A, Yamada SD, Krausz T. Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. Human Path 38:1569-1575, 2007. PMID 17889676
  35. Lotan T, Hickson J, Souris J, Huo D, Taylor J, Li T, Otto K, Yamada SD, Macleod K, Rinker-Schaeffer CW. c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 upregulation. Cancer Res 68(7):2166-75, 2008. PMID 18381422
  36. Sawada K, Mitra A, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. Loss of E-Cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68(7):2329-39, 2008. PMID 18381440
  37. Taylor J, Hickson J, Lotan T, Yamada SD, Rinker-Schaeffer C. Using metastasis-suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer Metastasis Rev 27(1):67-73, 2008. PMID 18049862
  38. Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol 111(3):537-9, 2008. PMID 18554701
  39. Hickson J, Yamada SD, Berger J, Alverdy J, O’Keefe J, Bassler B, Rinker-Schaeffer C. Societal interactions in ovarian cancer metastasis: a quorum sensing hypothesis. Clin Exp Metastasis 26(1):67-76, 2009. PMID 18516689
  40. Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Vander Griend D, Yamada SD, Macleod K, Rinker-Schaeffer CW. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett, 272(1):12-22, 2008. PMID 18572308
  41. Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/ DUSP1 in ovarian tissues. Clin Cancer Res 15(9):3196-204, 2009. PMID 19383827
  42. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E. B3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 175(5):2184-96, 2009. PMID 19808644
  43. Kenny HA, Dogan S, Zillhardt M, Mitra AK, Yamada SD, Krausz T, Lengyel E. Organotypic models of metastasis: a three-dimensional culture mimicking the human peritoneum and omentum for the study if the early steps of ovarian cancer metastasis. Cancer Treat Res 149:335-51, 2009. PMID 19763444
  44. Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, Buekers TE, Bell J, Schilder JM. A Phase II evaluation of weekly topotecan as a sngle agent second line therapyin persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 115(2):285-9, 2009. PMID 19726073
  45. De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. A phase II clinical trial of ixabepilone (BMS-247550) in patients with recurrent or persistent platinum and taxane resistant ovarian or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 28(1):149-153, 2010. PMID 19917861
  46. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 117(3):473-6, 2010. PMID 20347480
  47. Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, Warshal DP, Abulafia O, Richards WE, Van Le L. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 118(2):139-44, 2010. PMID 20452658
  48. Fracasso P, Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M. Low dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the the Gynecologic Oncology Group. Gynecol Oncol 120(2):224-8, 2011. PMID 21075438
  49. Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wrobleski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau ST. Assessing Gynecologic and Breast Cancer Survivors’ Sexual Health Care Needs. Cancer 117(12):2643-51, 2011. PMID 21656742
  50. Bishop EA, Lengyel ER, Yamada SD, Montag AG, Temkin SM. The Expression of Hepatocyte Growth Factor and c-Met in Uterine Serous Carcinoma. Gynecol Oncol. 121(1):218-23, 2011. PMID 21168200
  51. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag AG, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP. Lengyel ER. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 17(3):459-71, 2011. PMID 21149615
  52. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis, a Gynecologic Oncology Group trial. J Clin Oncol 29(1):69-75, 2011. PMID 21098323
  53. Zillhardt M, Park S, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an orally available multi-kinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 17(12):4042-51, 2011. PMID 21551255
  54. Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, DeGeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynec Oncol 121(2):264-8, 2011. PMID 21277623
  55. Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 123(2):182-6, 2011. PMID 21820161
  56. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adopicytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Med 17(11):1498-503, 2011. PMID 22037646
  57. Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125(1):54-8, 2012. PMID 22155262
  58. Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival and chemosensitivity. Obstet Gynecol 119(1):61-7, 2012. PMID 22183212
  59. Gotlieb WH, Amant F, Advani F, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomized, double-blind, placebo controlled study. Lancet Oncol 13(2):154-62, 2012. PMID 22192729
  60. Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson A, Fusco N, Fracasso PM. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 125(1):158-62, 2012. PMID 22198338
  61. Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CW. Time dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis 29(5):397-408, 2012. PMID 22350525
  62. Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol 127(2):316-20, 2012. PMID 22835717.
  63. Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 127(3):506-10, 2012. PMID 22943879.
  64. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm phase 2 study. Lancet Oncol 2012 Dec 20 Epub. PMID 23261356.
  65. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012 Dec 20. Epub. PMID 23262204.
  66. Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan Y. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 119(2):325-31, 2013. PMID 22806897.
  67. Goldfarb SB, Abramsohn E, Andersen BL, Baron SR, Carter J, Dickler M, Florendo J, Freeman L, Githens K, Kushner D, Makelarski JA, Yamada SD, Lindau ST. A national network to advance the field of cancer and female sexuality. J Sex Med 10(2):319-25, 2013. PMID 23350613.
  68. Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a Phase 2 Trial of the Gynecologic Oncology Group. Cancer 120(3):344-51, 2014. PMID: 24166194
  69. Sherman ME, Piedmonte MR, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro PA, Hamilton CA, Tewari KS, Wakeley KE, Kauff ND, Yamada SD, Rodriguez GC, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu KH, and Greene MH. Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy (RRSO): Primary Results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32(29):3275-83, 2014. PMID: 25199754
  70. West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol 1(2):151-4, 2014. PMID: 25541622
  71. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 124(10):4614-28, 2014. PMID: 25202979
  72. Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL. Statin therapy is associated with improved survival in patients with non-serous papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One 9(8):e104521, 2014. PMID: 25118694
  73. Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol 137(1):119-24, 2015. PMID: 25582823
  74. Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. In press. PMID: 25838164.

News

NCH specialists deliver individualized treatment to fallopian tube cancer patient

A rare gynecologic cancer diagnosis took 56-year-old Palatine resident Camille Snyder off guard more than two years ago. But after comprehensive treatment from a team of specialists at Northwest Community Healthcare, including renowned Gynecologic Oncologist Diane Yamada, M.D., Camille is thriving and enjoying her passions in life.

Read More

Discover advanced gynecologic cancer treatment close to home

Watch a video highlighting Northwest Community Healthcare’s Gynecologic Oncology Program, led by Rebecca Brooks, M.D. and Diane Yamada, M.D. Drs. Brooks and Yamada are experts in treating gynecologic cancers and offer patients comprehensive risk assessments and prevention programs.

Read More

NCH and University of Chicago Medicine collaborate to strengthen gynecological oncology care in northwest suburbs

Two gynecological oncology physicians from the University of Chicago Medicine are now caring for patients at Northwest Community Healthcare’s (NCH) Medical Group.

Read More